Functional Properties of <i>KIT</i> Mutations Are Associated with Differential Clinical Outcomes and Response to Targeted Therapeutics in CBF Acute Myeloid Leukemia.

导出 OA

翻译打印收藏纠错

作者： Katherine,Tarlock ^[1] ; Todd A,Alonzo ^[2] ; Yi-Cheng,Wang ^[3] ; Robert B,Gerbing ^[4] ; Rhonda,Ries ^[4] ; Michael R,Loken ^[4] ; Laura,Pardo ^[5] ; Tiffany,Hylkema ^[6] ; Jason,Joaquin ^[6] ; Leela,Sarukkai ^[5] ; Susana C,Raimondi ^[5] ; Betsy,Hirsch ^[5] ; Lillian,Sung ^[7] ; Richard,Aplenc ^[8] ; Irwin,Bernstein ^[9] ; Alan S,Gamis ^[10] ; Soheil,Meshinchi ^[5] ; Jessica A,Pollard ^[2]

作者单位： Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington. Katherine.tarlock@seattlechildrens.org. ^[1] Division of Hematology/Oncology, Seattle Children's Hospital, University of Washington, Seattle, Washington. ^[2] University of Southern California Keck School of Medicine, Los Angeles, California. ^[3] Children's Oncology Group, Monrovia, California. ^[4] Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington. ^[5] Hematologics, Inc, Seattle, Washington. ^[6] St Jude Children's Research Hospital, Memphis, Tennessee. ^[7] University of Minnesota Cancer Center, Minneapolis, Minnesota. ^[8] The Hospital for Sick Children, Toronto, Ontario, Canada. ^[9] The Children's Hospital of Philadelphia, Philadelphia, Pennsylvania. ^[10] Children's Mercy Hospitals and Clinics, Kansas City, Missouri. ^[11] Pediatric Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts. ^[12] Harvard Medical School, Boston, Massachusetts. ^[13]